Imugene Limited (AU:IMU) has released an update.
Imugene Limited is at the forefront of innovation in cancer treatment, showcasing their advancements at the upcoming AGM in November 2024. The company emphasizes caution for investors, urging them to seek professional advice before making investment decisions. Imugene’s presentation does not constitute an offer or solicitation for securities, especially in restricted jurisdictions like the United States.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
